Pharm Exec22 小时
IMU-856 Shows Promise in Celiac Disease: Histologic Protection and Nutrient Absorption Key ...
Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.
Pharm Exec23 小时
FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without Aura
Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...